$AstraZeneca PLC(AZN)$ As an AstraZeneca (AZN) shareholder, watching market-wide sell-offs is never fun—but moments like last week are exactly why I hold AZN in my portfolio.
When Wall Street takes a heavy beating, here is why I’m glad to own AZN:
* People don't pause cancer treatments: Market crashes don't change healthcare demand. AZN’s flagship oncology drugs (Tagrisso, Enhertu) generate non-negotiable revenue whether the economy is booming or sliding into a recession.
* Dividends keep paying me to wait: While tech gains evaporate overnight, AZN’s steady free cash flow pays reliable dividends that reinvest smoothly into market weakness.
* It grounds my portfolio: Low-beta defensive names like AZN don't plunge alongside high-flying growth stocks, shielding my overall portfolio from massive drawdowns.
* Driven by science, not interest rate rumors: AZN’s biggest catalysts—FDA approvals, Phase III trial results, and drug pipeline developments—happen completely independent of macroeconomic noise.
My takeaway: Wall Street pullbacks are a stark reminder of why balance matters. AZN acts as my portfolio's anchor—providing steady yield, downside protection, and peace of mind when market volatility strikes.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
